IDH1 Mar 1, 2021 Agios Submits sNDA for Tibsovo in IDH1-Mutant Bile Duct Cancer Dec 21, 2020 Agios Sells Oncology Business to Servier for $1.8B Upfront Oct 19, 2020 Agios Withdraws Tibsovo EU Marketing Application for IDH1-mutated Refractory AML Sep 21, 2020 Agios's Tibsovo Trial Fails to Meet Overall Survival Endpoint in IDH1-Mutated Bile Duct Cancer Jul 24, 2020 Chi-Med Initiates Phase I Trial of HMPL-306 in Hematological Malignancies With IDH1/2 Mutations Jun 9, 2020 Thermo Fisher Scientific, Agios Pharmaceuticals to Codevelop Glioma Companion Diagnostic Jun 5, 2020 Targeted Therapies Continue to Yield Encouraging Data in Studies of IDH-Mutated AML, Glioma Apr 13, 2020 Agios Pushing Ahead in IDH-Mutated Solid Tumors With Tibsovo, Vorasidenib Premium Oct 1, 2019 Trial Data Reveals Progression Delay in Cholangiocarcinoma with Targeted IDH1 Drug Jan 24, 2019 Memorial Sloan Kettering Using Cerebral Spinal Fluid Liquid Biopsy, Sequencing to Track Glioma Evolution Premium Aug 7, 2018 Researchers Integrate Genotyping Assay, Drug Delivery Tech for Precision Glioma Treatment Premium Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
